Integra LifeSciences (IART) Tops Q2 EPS by 8c ; Offers Guidance

Integra LifeSciences (NASDAQ: IART) reported Q2 EPS of $0.56, $0.08 better than the analyst estimate of $0.48. Revenue for the quarter came in at $418.8 million versus the consensus estimate of $417.62 million.

GUIDANCE:

Integra LifeSciences sees FY2026 EPS of $2.40-$2.50, versus the consensus of $2.45. Integra LifeSciences sees FY2026 revenue of $1.65-1.69 billion, versus the consensus of $1.67 billion.

Integra LifeSciences sees Q3 2026 EPS of $0.53-$0.61, versus the consensus of $0.57. Integra LifeSciences sees Q3 2026 revenue of $410-425 million, versus the consensus of $417.4 million.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• BofA maintains underperform ratings on six BDC stocks
• loanDepot receives NYSE non-compliance notice over stock price
• enVVeno Medical (NVNO) files $100M mixed shelf